Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Capital Expenditures (2016 - 2019)

Outlook Therapeutics (OTLK) has disclosed Capital Expenditures for 5 consecutive years, with $1.0 as the latest value for Q3 2019.

  • Quarterly Capital Expenditures fell 100.0% to $1.0 in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $437307.0 through Sep 2019, down 84.28% year-over-year, with the annual reading at $437307.0 for FY2019, 84.28% down from the prior year.
  • Capital Expenditures for Q3 2019 was $1.0 at Outlook Therapeutics, up from -$657960.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $3.5 million in Q2 2015, with the low at -$887322.0 in Q2 2018.
  • Average Capital Expenditures over 5 years is $632910.3, with a median of $271787.0 recorded in 2017.
  • Peak annual rise in Capital Expenditures hit 763.72% in 2018, while the deepest fall reached 427.61% in 2018.
  • Over 5 years, Capital Expenditures stood at $364242.0 in 2015, then plummeted by 59.27% to $148362.0 in 2016, then soared by 624.68% to $1.1 million in 2017, then tumbled by 78.01% to $236433.0 in 2018, then tumbled by 100.0% to $1.0 in 2019.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $1.0, -$657960.0, and $858833.0 for Q3 2019, Q2 2019, and Q1 2019 respectively.